Teleflex to Acquire BIOTRONIK’s Vascular Intervention Business for €760 Million
Deal News | Feb 27, 2025 | Goodwin
Teleflex Incorporated has entered into a definitive agreement to acquire the Vascular Intervention business of BIOTRONIK SE & Co. KG for an estimated €760 million in cash. The purchase involves a range of cardiovascular devices such as drug-coated balloons and stents, expected to close by Q3 2025. Driven by its mission to be a leader in healthcare solutions, Teleflex aims to expand its reach in the interventional cardiology and peripheral vascular markets, estimated to be worth $10 billion. The acquisition remains conditional on regulatory approvals and customary adjustments at close. Goodwin's M&A and Life Sciences teams, led by advisors Rob Masella, Amanda Gill, Markus Kpplinger, and Adam Bellack, managed the advisory work. Teleflex aims to strengthen its position in medical technologies, offering enhanced solutions in anesthesia, emergency medicine, interventional radiology, surgical, vascular access, and urology.
Sectors
- Medical Technology
- Healthcare Equipment & Services
Geography
- Global – Teleflex is a global provider, and the acquisition affects the worldwide market for medical technologies, with operations likely impacting multiple regions.
- Germany – BIOTRONIK SE & Co. KG is based in Germany, which plays a significant role in this transaction.
- United States – Teleflex Incorporated is headquartered in the United States, making the USA a primary influential region in this deal.
Industry
- Medical Technology – The acquisition involves companies that operate in the medical technology sector, specializing in interventional cardiology and vascular intervention devices.
- Healthcare Equipment & Services – The deal pertains to the healthcare equipment industry as it involves the acquisition of various cardiovascular devices, expanding Teleflex's diverse healthcare solutions portfolio.
Financials
- €760 million – The estimated cash payment by Teleflex for acquiring BIOTRONIK's Vascular Intervention business, subject to adjustments.
- $10 billion – The estimated market size of the interventional cardiology and peripheral vascular market post-acquisition.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Teleflex Incorporated | Acquiring Company | Company | A global provider of medical technologies, engaged in acquiring BIOTRONIK's Vascular Intervention business. |
| BIOTRONIK SE & Co. KG | Target Company | Company | A German company specializing in medical technologies, targeted for acquisition by Teleflex. |
| Goodwin | Legal Advisor | Company | Provided legal advisory services to Teleflex for the acquisition deal. |
| Rob Masella | Advisor | Person | Part of the Goodwin team leading the advisory services for the acquisition. |
| Amanda Gill | Advisor | Person | Part of the Goodwin team leading the advisory services for the acquisition. |
| Markus Kpplinger | Advisor | Person | Part of the Goodwin team leading the advisory services for the acquisition. |
| Adam Bellack | Advisor | Person | Part of the Goodwin team leading the advisory services for the acquisition. |